TY - JOUR
T1 - Gut microbiome-mediated mechanisms for reducing cholesterol levels
T2 - implications for ameliorating cardiovascular disease
AU - Jia, Baolei
AU - Zou, Yuanqiang
AU - Han, Xiao
AU - Bae, Jin Woo
AU - Jeon, Che Ok
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2023/1
Y1 - 2023/1
N2 - Cardiovascular disease (CVD) is a health problem worldwide, and elevated cholesterol levels are a key risk factor for the disease. Dysbiotic gut microbiota has been shown to be associated with CVD development. However, the beneficial effects of healthy microbiota in decreasing cholesterol levels have not been summarized. Herein, we begin by discussing the potential mechanisms by which the gut microbiota reduces cholesterol levels. We further sketch the application of probiotics from the genera Lactobacillus and Bifidobacterium in reducing cholesterol levels in clinical studies. Finally, we present the cholesterol-lowering function of beneficial commensal microbes, such as Akkermansia and Bacteroides spp., as these microbes have potential to be the next-generation probiotics (NGPs). The information reviewed in this paper will help people to understand how the gut microbiome might alter cholesterol metabolism and enable the development of NGPs to prevent and treat CVD.
AB - Cardiovascular disease (CVD) is a health problem worldwide, and elevated cholesterol levels are a key risk factor for the disease. Dysbiotic gut microbiota has been shown to be associated with CVD development. However, the beneficial effects of healthy microbiota in decreasing cholesterol levels have not been summarized. Herein, we begin by discussing the potential mechanisms by which the gut microbiota reduces cholesterol levels. We further sketch the application of probiotics from the genera Lactobacillus and Bifidobacterium in reducing cholesterol levels in clinical studies. Finally, we present the cholesterol-lowering function of beneficial commensal microbes, such as Akkermansia and Bacteroides spp., as these microbes have potential to be the next-generation probiotics (NGPs). The information reviewed in this paper will help people to understand how the gut microbiome might alter cholesterol metabolism and enable the development of NGPs to prevent and treat CVD.
KW - bile acids
KW - hypercholesterolemia
KW - live biotherapeutic products
KW - short-chain fatty acids
KW - steroid
UR - http://www.scopus.com/inward/record.url?scp=85136581798&partnerID=8YFLogxK
U2 - 10.1016/j.tim.2022.08.003
DO - 10.1016/j.tim.2022.08.003
M3 - Review article
C2 - 36008191
AN - SCOPUS:85136581798
SN - 0966-842X
VL - 31
SP - 76
EP - 91
JO - Trends in Microbiology
JF - Trends in Microbiology
IS - 1
ER -